The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
Paul M. Barr
Research Funding - Gilead Sciences
Gene Brian Saylors
No relevant relationships to disclose
Stephen Edward Forbes Spurgeon
Research Funding - Gilead Sciences
Bruce D. Cheson
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Daniel Reif Greenwald
No relevant relationships to disclose
Susan Mary O'Brien
Research Funding - Gilead Sciences
Andre K. D. Liem
No relevant relationships to disclose
Rosemary McIntyre
No relevant relationships to disclose
Esteban Abella-Dominicis
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Michael J. Hawkins
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Anita Reddy
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Julie Di Paolo
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Meihua Wu
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Flordeliza Melchor-Khan
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Feng Jin
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Jonathan W. Friedberg
No relevant relationships to disclose